Dopa Decarboxylase

One of the AROMATIC-L-AMINO-ACID DECARBOXYLASES, this enzyme is responsible for the conversion of DOPA to DOPAMINE. It is of clinical importance in the treatment of Parkinson's disease.

Also Known As:

Networked: 230 relevant articles (12 outcomes, 25 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Müller, Thomas: 4 articles (09/2017 - 05/2002)
2.	Hauser, Robert A: 3 articles (01/2019 - 05/2007)
3.	Montioli, Riccardo: 3 articles (01/2016 - 12/2011)
4.	Cellini, Barbara: 3 articles (01/2012 - 01/2007)
5.	Gordin, A: 3 articles (10/2004 - 01/2001)
6.	Scott, Lesley J: 2 articles (01/2021 - 09/2016)
7.	Bertoldi, Mariarita: 2 articles (01/2016 - 01/2007)
8.	Giegling, Ina: 2 articles (11/2014 - 04/2008)
9.	Rietschel, Marcella: 2 articles (11/2014 - 07/2002)
10.	Rujescu, Dan: 2 articles (11/2014 - 04/2008)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 11/01/2001 - "Structural insight into Parkinson's disease treatment from drug-inhibited DOPA decarboxylase." 02/01/1996 - "Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease." 01/01/1993 - "For the caudate nucleus, the DOPA decarboxylase activity (k3D, k3*), tissue slope-intercept plots (kr3, ks3); and striato-occipital ratio [R(T)] analyses significantly discriminated between the normal volunteers and the patients with Parkinson's disease (p < 0.005) [with least significance for k3* (p < 0.05)], while the plasma slope-intercept plot (K) failed to do so. " 05/01/1998 - "Current in vivo assays of dopa decarboxylase activity fail to discriminate clinically distinct stages in the progression of Parkinson's disease and are, by themselves, insufficient for differential diagnosis of Parkinson's disease and other subcortical movement disorders. " 05/01/1998 - "Abnormally low influx of dopa decarboxylase tracers in the basal ganglia is characteristic of Parkinson's disease and other movement disorders. "
2.	Dyskinesias (Dyskinesia) 07/01/2008 - "However, long-term treatment with conventional formulations [levodopa and a dopa decarboxylase inhibitor (DDCI)], is associated with re-emergence of symptoms because of wearing-off and dyskinesia. " 07/01/2006 - "Unfortunately, chronic use of traditional levodopa/dopa decarboxylase inhibitor formulations is associated with the development of complications, such as wearing-off and dyskinesia. " 12/01/1984 - "One year ago peripheral dopa decarboxylase inhibitor in combination with L-dopa was started, and he began to have involuntary movements. " 06/10/2010 - "The novel dopa decarboxylase inhibitor, L-AMD, increased locomotor activity and improved motor disability to the same extent as carbidopa or benserazide but importantly this was accompanied by significantly less dyskinesia. " 06/02/2016 - "We used the 6-hydroxydopamine (6-OHDA) rat model of PD treated with a three-week dosing regimen of L-DOPA plus the dopa decarboxylase inhibitor benserazide (4 mg/kg and 7.5 mg/kgs.c., respectively) to induce dyskinesia in 50% of individuals. "
3.	Pain (Aches) 03/12/2022 - "The OpiCapone Effect on motor fluctuations and pAiN (OCEAN) trial aims to investigate the efficacy of OPC 50 mg in PD patients with end-of-dose motor fluctuations and associated pain, when administered as adjunctive therapy to existing treatment with levodopa/dopa decarboxylase inhibitor (DDCi). "
4.	Parkinsonian Disorders (Parkinsonism) 09/19/2023 - "We evaluated the cardiovascular effect of LD performing head-up tilt test (HUTT) before and 60 min after 100/25 mg LD/dopa-decarboxylase inhibitor (pre-LD vs. post-LD HUTT) in 164 patients with parkinsonism on chronic LD treatment. " 03/01/1981 - "Levodopa with or without dopa decarboxylase is not a cure for parkinsonism. " 01/01/2020 - "Here we show that optogenetic activation of substantia nigra pars compacta (SNpc) neurons alleviates parkinsonism in acute PD animal models by recovering tyrosine hydroxylase (TH) from the TH-negative dormant dopaminergic neurons, some of which still express DOPA decarboxylase (DDC). " 01/01/1985 - "Autonomic cardiovascular responses in parkinsonism: effect of levodopa with dopa-decarboxylase inhibition." 12/01/1984 - "Suppression of L-dopa-induced circling in rats with nigral lesions by blockade of central dopa-decarboxylase: implications for mechanism of action of L-dopa in parkinsonism."
5.	Neuroblastoma 02/17/1978 - "There was significant antitumor activity against the neuroblastoma, which was enhanced by combination with a dopa decarboxylase inhibitor, Ro4-4602. " 01/01/1985 - "Using the neuroblastoma clone N1E-115 which lacks DOPA decarboxylase and thus contains only low levels of dopamine the site of action of certain drugs could be determined. " 07/01/1999 - "Of the 29 non-neuroblastoma tumor samples examined, the only tumor samples that expressed clearly detectable levels of both tyrosine hydroxylase and dopa decarboxylase were phaeochromocytomas. " 04/01/2010 - "Tyrosine hydroxylase and 3,4-dihydroxyphenylalanine (dopa) decarboxylase transcripts were demonstrated in 10 of 13 cases of neuroblastoma. " 12/15/2008 - "Tyrosine hydroxylase (TH), dopa decarboxylase (DDC) and GD2 synthase (GD2S) mRNAs were analyzed in 554 blood (PB) and bone marrow (BM) samples from 58 children with neuroblastoma. "

Related Drugs and Biologics

1.	Levodopa (L Dopa)
2.	entacapone (Comtan)
3.	Dopamine (Intropin)
4.	Tyrosine 3-Monooxygenase (Tyrosine Hydroxylase)
5.	Carbidopa (Lodosyn)
6.	Enzymes
7.	Dihydroxyphenylalanine (Dopa)
8.	Benserazide
9.	opicapone
10.	Bromocriptine (Parlodel)

Related Therapies and Procedures

1.	Therapeutics
2.	Transcranial Direct Current Stimulation
3.	Transcranial Magnetic Stimulation
4.	Infusion Pumps (Infusion Pump)
5.	Drug Therapy (Chemotherapy)